ISAB — Inhalation Sciences Sweden AB Balance Sheet
0.000.00%
- SEK15.59m
- SEK5.87m
- SEK11.05m
Annual balance sheet for Inhalation Sciences Sweden AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | SAS | SAS | SAS | SAS | SAS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 8.05 | 14.4 | 1.84 | 7.83 | 4.45 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.98 | 3.11 | 2.95 | 4.3 | 1.65 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 12.9 | 21.5 | 9.5 | 15.8 | 9.28 |
| Net Property, Plant And Equipment | 1.14 | 1.04 | 0.837 | 0.651 | 0.512 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 18.5 | 26.1 | 13 | 18.2 | 10.5 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 6.12 | 5.07 | 4.57 | 4.77 | 2.72 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 8.01 | 6.43 | 5.43 | 5.21 | 2.72 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 10.5 | 19.7 | 7.55 | 13 | 7.81 |
| Total Liabilities & Shareholders' Equity | 18.5 | 26.1 | 13 | 18.2 | 10.5 |
| Total Common Shares Outstanding |